Chronic lymphocytic leukaemia+5
RecruitingStudy of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment
Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment
- Disease:Chronic lymphocytic leukaemiaChronic lymphocytic leukaemia refractory+4
- Substances:–
Poland- Participants:18–64 years · 65+ years
- Sponsor:Nurix Therapeutics Inc.










